CATX insider trading
NYSE American HealthcarePerspective Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha; and PSV4XX, a differentiated prostate-specific membrane antigen-targeted alpha therapy. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Company website: www.perspectivetherapeutics.com
CATX insider activity at a glance
FilingIQ tracks 62 insider transactions for CATX in filings since Dec 18, 2023. The most recent transaction is dated Sep 4, 2026.
Across the full history, 54 open-market purchases
and 7 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
How FilingIQ classifies each line, and the seven facts it shows on every open-market purchase and sale, are documented on the methodology page.
Latest CATX Form 4 filings
Most recent disclosures. Sign up to filter by transaction code, insider role or dollar value.
Other Healthcare tickers with recent insider activity
Most active insiders at CATX
By number of Form 4 lines in the last 180 days.
Frequently asked
- How many insider trades does FilingIQ track for CATX?
- FilingIQ tracks 62 Form 4 insider transactions for CATX (Perspective Therapeutics, Inc.), covering filings from Dec 18, 2023 onwards. 7 of those are dated within the last 90 days.
- Are CATX insiders net buyers or net sellers?
- Across the full Form 4 history for CATX, 54 transactions (87%) were open-market purchases and 7 (11%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CATX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ links every filing to the insider's SEC CIK, marks plan trades, tax withholding, option exercises, gifts, derivatives and amendments, and shows each open-market purchase and sale with the same fixed facts. It does not rate the stock.
- What sector is CATX in?
- Perspective Therapeutics, Inc. (CATX) is classified in the Healthcare sector, specifically Medical Devices, with a current market capitalisation of $582.10M.
Methodology & sources
Every CATX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). How lines are classified and which facts FilingIQ adds is documented on the methodology page; the people behind it are on the team page. Not investment advice; see disclaimer.